Natural killer cells license dendritic cell cross-presentation of B lymphoma cell–associated antigens

PMID: 16361564
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (volume: 11, issue: 24 Pt 1, Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-72)
Published: 2005-12-15

Authors:
Dao T, Gomez-Nunez M, Antczak C, Kappel B, Jaggi JS, Korontsvit T, Zakhaleva V, Scheinberg DA

ABSTRACT

PURPOSE: Presentation of exogenous antigen by MHC class I molecules, or cross-presentation, is a property of dendritic cells, which is considered crucial for the priming of cytotoxic T-cell response to tumor antigens. However, the precise mechanisms of this process are not fully understood.

EXPERIMENTAL DESIGN AND RESULTS: We show here in a human in vitro system, using B lymphoma cells as a tumor model, that the cross-presentation of cell-associated antigens to T cells by dendritic cells requires „help“ from natural killer cells. When autologous dendritic cells that had taken up apoptotic B lymphoma cells and induced to a fully mature state were used to stimulate nonadherent cells of peripheral blood mononuclear cells from healthy donors, they induced strong cytotoxicity against B lymphoma cells in a HLA-A0201-restricted manner. The cells failed to induce cytotoxicity, however, when purified T cells were used as effector cells. Depletion of CD56+ cells, but not CD14+ or CD19+ cells, abrogated the cytotoxicity of nonadherent cells, showing that the help was provided by natural killer cells. Further, when natural killer cells were present in the cultures, a strong and persistent production of interleukin-18, but not interleukin-12 and interleukin-15, was observed. Blocking interleukin-18 significantly reduced the cytotoxicity of nonadherent cells against B lymphoma cells.

CONCLUSIONS: These results suggest that capture of tumor cells and a full maturation status of dendritic cells are not sufficient to cross-prime CD8 T cells. Effective cross-priming requires further activation of dendritic cells by natural killer cells and an abundant production of interleukin-18, which, along with other yet undefined mechanisms, contribute to the generation of CTL response against B-cell lymphoma.